Penumbra, Inc. (NYSE:PEN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
|
(a)
|
Penumbra, Inc. (Penumbra or the Company) held its Annual
Meeting of Stockholders on June 7, 2017 (Annual Meeting). Proxies for the Annual Meeting were solicited to Regulation 14A of the Securities Exchange Act of 1934, as amended. At the close of business on the record date, April 12, 2017, there were 33,627,160 shares outstanding and entitled to vote, and 30,338,153 shares were voted in person or by proxy on the proposals described below. |
|
(b)
|
At the Annual Meeting, Penumbras stockholders voted on the
following four proposals, each of which is described in more detail in the Companys definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2017. The number of votes cast with respect to each proposal was as indicated below: |
|
1)
|
Election of Class II Directors. The following nominees were
elected to serve as Class II directors, each to serve until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified, based on the following results of voting: |
|
Nominee
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
Arani Bose, M.D.
|
|
19,775,139
|
|
3,836,563
|
|
23,702
|
|
6,702,749
|
|
Bridget O’Rourke
|
|
23,552,615
|
|
57,313
|
|
25,476
|
|
6,702,749
|
|
2)
|
Ratification of Selection of Independent Registered Public
Accounting Firm. The selection of Deloitte Touche LLP as the independent registered public accounting firm for Penumbra for the fiscal year ending December 31, 2017 was ratified based on the following results of voting: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
30,290,563
|
|
10,103
|
|
37,487
|
|
N/A
|
|
3)
|
Approval, on an Advisory Basis, of the Compensation of the
Companys Named Executive Officers.>The compensation of the Companys Named Executive Officers was approved, on an advisory basis, based on the following results of voting: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
23,317,359
|
|
291,271
|
|
26,774
|
|
6,702,749
|
|
4)
|
Approval, on an Advisory Basis, of the Frequency of Future
Advisory Votes on Named Executive Officer Compensation.>The annual frequency of future advisory votes on Named Executive Officer compensation was approved, on an advisory basis, based on the following results of voting: |
|
One Year
|
|
Two Years
|
|
Three Years
|
|
Abstentions
|
|
22,060,481
|
|
314,790
|
|
1,233,674
|
|
26,459
|
About Penumbra, Inc. (NYSE:PEN)
Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company’s peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.
